Use of receptor-type oncogene c-ergB-2 for the diagnosis and treatment of human cancers

a.我们引入ELISA和RIA建立了血清c-ErbB-2蛋白水平的定量方法，结果稳定可靠。福利部目前正在评估这一系统的临床使用情况。在c-erbB-2基因、产物和相关基因方面获得了如下新发现：i证实了Ehrs作为c-erbB-2蛋白的配体发挥作用; ii发现了新的受体型酪氨酸激酶brt; iii鉴定了一种新的致癌嵌合蛋白酪氨酸激酶P80; iv揭示了c-erbB-2基因的启动子位点; v Fgr，src型酪氨酸激酶显示与IgGFc受体II相关。

a. We established the method for quantitation of serum c-ErbB-2 protein levels with the introduction of ELISA and RIA.The outcome was shown to be stable and reliable. This system is now under evaluation for clinical use at the Ministry of Welfare.b. The following new findings were obtained concerning the c-erbB-2 gene, product, and related genes.i The Estradiol was shown to work as a ligant for the c-ErbB-2 protein.ii New receptor-type tyrosine kinase brt was found.iii A new oncogenic chimeric protein tyrosine kinase P80 was identified.iv The promoter site of c-erbB-2 gene was revealed.v Fgr, a src-type tyrosine kinase was shown to associate with IgG Fc receptor II.